Abiopharma

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Claritev Corporation Announces First Quarter 2026 Earnings Conference Call

Abacus Global Management to Participate in the 2026 Milken Institute Global Conference

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

Hadron Energy Aligns Valuation for Business Combination to $600M, Signaling Long-Term Market Discipline After GigCapital7 Form S-4 Registration Statement Declared Effective

MaxsMaking Inc. Commences U.S. Business Operations

Fusion Fuel Highlights Announced Exploration Plan at Jaguar Uranium’s Huemul Project, Potential Royalty Portfolio Income

CenterWell Introduces the Fulfillment Index, a New Measure of What It Means to Age Well

Rayonier Advanced Materials Announces Comprehensive Strategic Alternatives Review to Maximize Shareholder Value